Patents Examined by Robert Gersh
  • Patent number: 6750255
    Abstract: A novel calcium receptor active compound having the formula is provided: Ar1—[CR1R2]p—X—[CR3R4]q—[CR5R6]—NR7—[CR8R9]—Ar2 wherein: Ar1 is selected from the group consisting of aryl, heteroaryl, bis(arylmethyl)amino, bis(heteroarylmethyl)amino and arylmethyl(heteroarylmethyl)amino; X is selected from the group consisting of oxygen, sulfur, sulfinyl, sulfonyl, carbonyl and amino; R1, R2, R3, R4, R5, R6, R7, R8 and R9 are, for example, hydrogen or alkyl; Ar2 is selected from the group consisting of aryl and heteroaryl; p is an integer of from 0 to 6, inclusive; and, q is an integer of from 0 to 14, inclusive.
    Type: Grant
    Filed: January 17, 2002
    Date of Patent: June 15, 2004
    Assignees: NPS Pharmaceuticals, Inc., Kirin Beer Kabushiki
    Inventors: Teruyuki Sakai, Atsuya Takami, Rika Nagao
  • Patent number: 5260329
    Abstract: The invention relates to ureido derivatives of substituted pyrroles of formula ##STR1## wherein each of m and n, being the same, is an integer of 1 to 3; W is oxygen of sulphur;each of the B groups, which are the same, isa) a saturated or unsaturated, carbocyclic or condensed carbocyclic ring substituted by one or more acid groups;b) a saturated or unsaturated, heteromonocyclic or heterobicyclic ring, containing one or more heteroatoms chosen from nitrogen, oxygen and sulphur, substituted by one or more acid groups;c) a pyranyl or furanyl sugar residue substituted by one or more acid groups; ord) a --CH.sub.2 (CHA).sub.r CH.sub.2 A group, wherein each A group, being the same or different, is an acid group and r is 0, 1 or 2; and the pharmaceutically acceptable salts thereof, which areuseful as angiogenesis inhibitors.
    Type: Grant
    Filed: September 9, 1991
    Date of Patent: November 9, 1993
    Assignee: Farmitalia Carlo Erba Srl
    Inventors: Nicola Mongelli, Giovanni Biasoli, Alfredo Paio, Maria Grandi, Marina Ciomei
  • Patent number: 3940438
    Abstract: The invention concerns a novel crystalline racemate, 9.alpha.,11.alpha.,15(S)-trihydroxy-5-cis,13-trans-prostadienoic acid. The racemate can be administered in pharmaceutical dosage forms or from a drug delivery device at a programmed rate for producing smooth muscle stimulation, termination of pregnancy, induction of labor or induction of menses.
    Type: Grant
    Filed: September 21, 1973
    Date of Patent: February 24, 1976
    Assignee: Alza Corporation
    Inventor: Ned M. Weinshenker
  • Patent number: 3936487
    Abstract: This invention is a group of 3- and 4-oxa PG type compounds, and processes for making them. These compounds are useful for a variety of pharmacological purposes, including anti-ulcer, inhibition of platelet aggregation, increase of nasal patency, labor inducement at term, and wound healing.
    Type: Grant
    Filed: April 17, 1974
    Date of Patent: February 3, 1976
    Assignee: The Upjohn Company
    Inventor: Norman A. Nelson